Trial Profile
First-line Treatment for Grade 1-3A Follicular Lymphoma Using Opdivo (Nivolumab) Plus Rituximab: The 1st FLOR Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Feb 2023
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Rituximab (Primary)
- Indications Follicular lymphoma
- Focus Adverse reactions
- Acronyms 1stFLOR
- 18 Jul 2022 Planned End Date changed from 1 Jun 2024 to 1 Jun 2027.
- 18 Jul 2022 Planned primary completion date changed from 1 Jun 2022 to 1 Sep 2022.
- 18 Jul 2022 Status changed from recruiting to active, no longer recruiting.